PDCD1 and neoplasm: The frequency of cells expressing the checkpoint ligand PD-L1 were very low under all therapeutic combinations (Fig. 2k), consistent with this tumour model not exhibiting a strong PD-L1/PD-1 mediated suppression of T cell activation.